Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome

Aakash Bavishi, Travis Howard, Jooho P. Kim, Brent Hiramoto, Jacob B. Pierce, Parrykumar Mendapara, Jonathan Alhalel, Han Wei Wu, Nina Srdanovich, Neil J Stone

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Previous studies assessing healthcare provider compliance to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines indicate a significant underuse of statin therapy at appropriate intensity. However, data are limited in primary prevention patients. Our study aimed to evaluate the impact of the 2013 ACC/AHA guidelines through a retrospective analysis of primary prevention patients presenting with first time acute coronary syndrome (ACS). We retrospectively calculated the 10-year predicted Atherosclerotic Cardiovascular Disease (10yASCVD) risk in 1,265 patients ages 40 to 75 who presented with ACS and no previous ASCVD. In patients without known ambulatory systolic blood pressure, a multivariable linear regression model was used to predict outpatient systolic blood pressure. Outcomes analyzed in each 10yASCVD category included statin status and statin intensity (high/medium/low) with further categorization by type of ACS event and date of left heart catheterization. In both primary analysis and sensitivity analysis (patients with predicted systolic blood pressure), statistical significance was shown with respect to overall statin status, ST Elevation Myocardial Infarction, and date of left heart catheterization. In summary, retrospective calculation of 10yASCVD in patients with a first ACS event showed a significant number of ACS patients would have qualified for statin therapy per 2013 ACC/AHA guidelines before their event but had not been initiated on one.

Original languageEnglish (US)
Pages (from-to)368-374
Number of pages7
JournalAmerican Journal of Cardiology
Volume123
Issue number3
DOIs
StatePublished - Feb 1 2019

Fingerprint

Primary Prevention
Acute Coronary Syndrome
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Blood Pressure
American Heart Association
Cardiovascular Diseases
Guidelines
Cardiac Catheterization
Cardiology
Therapeutics
Linear Models
Health Personnel
Outpatients
Cholesterol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bavishi, Aakash ; Howard, Travis ; Kim, Jooho P. ; Hiramoto, Brent ; Pierce, Jacob B. ; Mendapara, Parrykumar ; Alhalel, Jonathan ; Wu, Han Wei ; Srdanovich, Nina ; Stone, Neil J. / Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome. In: American Journal of Cardiology. 2019 ; Vol. 123, No. 3. pp. 368-374.
@article{2d3c6091eda54161a86f4a65f593dc16,
title = "Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome",
abstract = "Previous studies assessing healthcare provider compliance to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines indicate a significant underuse of statin therapy at appropriate intensity. However, data are limited in primary prevention patients. Our study aimed to evaluate the impact of the 2013 ACC/AHA guidelines through a retrospective analysis of primary prevention patients presenting with first time acute coronary syndrome (ACS). We retrospectively calculated the 10-year predicted Atherosclerotic Cardiovascular Disease (10yASCVD) risk in 1,265 patients ages 40 to 75 who presented with ACS and no previous ASCVD. In patients without known ambulatory systolic blood pressure, a multivariable linear regression model was used to predict outpatient systolic blood pressure. Outcomes analyzed in each 10yASCVD category included statin status and statin intensity (high/medium/low) with further categorization by type of ACS event and date of left heart catheterization. In both primary analysis and sensitivity analysis (patients with predicted systolic blood pressure), statistical significance was shown with respect to overall statin status, ST Elevation Myocardial Infarction, and date of left heart catheterization. In summary, retrospective calculation of 10yASCVD in patients with a first ACS event showed a significant number of ACS patients would have qualified for statin therapy per 2013 ACC/AHA guidelines before their event but had not been initiated on one.",
author = "Aakash Bavishi and Travis Howard and Kim, {Jooho P.} and Brent Hiramoto and Pierce, {Jacob B.} and Parrykumar Mendapara and Jonathan Alhalel and Wu, {Han Wei} and Nina Srdanovich and Stone, {Neil J}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.amjcard.2018.10.034",
language = "English (US)",
volume = "123",
pages = "368--374",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

Bavishi, A, Howard, T, Kim, JP, Hiramoto, B, Pierce, JB, Mendapara, P, Alhalel, J, Wu, HW, Srdanovich, N & Stone, NJ 2019, 'Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome', American Journal of Cardiology, vol. 123, no. 3, pp. 368-374. https://doi.org/10.1016/j.amjcard.2018.10.034

Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome. / Bavishi, Aakash; Howard, Travis; Kim, Jooho P.; Hiramoto, Brent; Pierce, Jacob B.; Mendapara, Parrykumar; Alhalel, Jonathan; Wu, Han Wei; Srdanovich, Nina; Stone, Neil J.

In: American Journal of Cardiology, Vol. 123, No. 3, 01.02.2019, p. 368-374.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment Gap in Primary Prevention Patients Presenting With Acute Coronary Syndrome

AU - Bavishi, Aakash

AU - Howard, Travis

AU - Kim, Jooho P.

AU - Hiramoto, Brent

AU - Pierce, Jacob B.

AU - Mendapara, Parrykumar

AU - Alhalel, Jonathan

AU - Wu, Han Wei

AU - Srdanovich, Nina

AU - Stone, Neil J

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Previous studies assessing healthcare provider compliance to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines indicate a significant underuse of statin therapy at appropriate intensity. However, data are limited in primary prevention patients. Our study aimed to evaluate the impact of the 2013 ACC/AHA guidelines through a retrospective analysis of primary prevention patients presenting with first time acute coronary syndrome (ACS). We retrospectively calculated the 10-year predicted Atherosclerotic Cardiovascular Disease (10yASCVD) risk in 1,265 patients ages 40 to 75 who presented with ACS and no previous ASCVD. In patients without known ambulatory systolic blood pressure, a multivariable linear regression model was used to predict outpatient systolic blood pressure. Outcomes analyzed in each 10yASCVD category included statin status and statin intensity (high/medium/low) with further categorization by type of ACS event and date of left heart catheterization. In both primary analysis and sensitivity analysis (patients with predicted systolic blood pressure), statistical significance was shown with respect to overall statin status, ST Elevation Myocardial Infarction, and date of left heart catheterization. In summary, retrospective calculation of 10yASCVD in patients with a first ACS event showed a significant number of ACS patients would have qualified for statin therapy per 2013 ACC/AHA guidelines before their event but had not been initiated on one.

AB - Previous studies assessing healthcare provider compliance to the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines indicate a significant underuse of statin therapy at appropriate intensity. However, data are limited in primary prevention patients. Our study aimed to evaluate the impact of the 2013 ACC/AHA guidelines through a retrospective analysis of primary prevention patients presenting with first time acute coronary syndrome (ACS). We retrospectively calculated the 10-year predicted Atherosclerotic Cardiovascular Disease (10yASCVD) risk in 1,265 patients ages 40 to 75 who presented with ACS and no previous ASCVD. In patients without known ambulatory systolic blood pressure, a multivariable linear regression model was used to predict outpatient systolic blood pressure. Outcomes analyzed in each 10yASCVD category included statin status and statin intensity (high/medium/low) with further categorization by type of ACS event and date of left heart catheterization. In both primary analysis and sensitivity analysis (patients with predicted systolic blood pressure), statistical significance was shown with respect to overall statin status, ST Elevation Myocardial Infarction, and date of left heart catheterization. In summary, retrospective calculation of 10yASCVD in patients with a first ACS event showed a significant number of ACS patients would have qualified for statin therapy per 2013 ACC/AHA guidelines before their event but had not been initiated on one.

UR - http://www.scopus.com/inward/record.url?scp=85057184494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057184494&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2018.10.034

DO - 10.1016/j.amjcard.2018.10.034

M3 - Article

VL - 123

SP - 368

EP - 374

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -